Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Rucaparib effective as maintenance therapy following first-line platinum-based c...

Dr Bradley Monk - University of Arizona College, Tucson, USA

21 Jun 2022

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advan...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

17 Jun 2022

ASCO 2022: The latest in RCC

Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri

17 Jun 2022

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

14 Jun 2022

A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...

Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands

$A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )$

13 Jun 2022

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

13 Jun 2022

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

13 Jun 2022

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute mye...

Dr Harry Erba - The Duke Cancer Institue, Durham, USA